Bismuth Subcitrate Potassium
drugOn this page
Also known as Bismuth subcitrate
Summary
Bismuth Subcitrate Potassium (CHEMBL1201186) is an approved small molecule (ATC A02BX05); indicated across 6 conditions including peptic ulcer disease and gastroesophageal reflux disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A02BX05
- Indications: 6 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201186 |
| Name | Bismuth Subcitrate Potassium |
| Type | Small molecule |
| Max phase | 4 |
| ATC | A02BX05 |
Also known as: Bismuth subcitrate, Bismuth subcitrate potassium, BISMUTH SUBCITRATE POTASSIUM, Bismuth Subcitrate Potassium
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| peptic ulcer disease | 4 | MONDO:0004247 | HP:0004398 |
| gastroesophageal reflux disease | 4 | MONDO:0007186 | EFO:0003948 |
| duodenal ulcer | 4 | MONDO:0005412 | EFO:0004607 |
| Helicobacter pylori infectious disease | 3 | MONDO:0006781 | EFO:1000961 |
| gastric ulcer | 3 | MONDO:0001126 | EFO:0009454 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| PHASE2 | 2 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01335334 | PHASE4 | UNKNOWN | H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study |
| NCT04101708 | PHASE4 | UNKNOWN | A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients |
| NCT04853875 | PHASE4 | COMPLETED | ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin |
| NCT06143124 | PHASE4 | UNKNOWN | Bismuth Quadruple Therapy Versus Standard Triple Therapy |
| NCT04107194 | PHASE3 | UNKNOWN | Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. |
| NCT00003151 | PHASE2 | COMPLETED | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma |
| NCT01876108 | PHASE2 | COMPLETED | The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease |
| NCT03925818 | Not specified | TERMINATED | Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication |
| NCT06216639 | Not specified | UNKNOWN | Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).